Developing immune-oncology products for the treatment of cancers with unmet needs
About our Company
H2Biologics is designing novel proteins for cancers such as pancreatic, ovarian, lung, and mesothelioma that continue to have poor survival rates and prognoses. The success of the Company’s therapeutic approach is based on safely delivering naturally occurring human Granzyme B, a high-powered cytotoxic molecule employed by the immune system to kill target cells. This strategy maximizes anti-tumor efficacy while minimizing the safety concerns encountered with other immunotoxins.
Our Science
Exploiting the Power of Granzyme B
The Management Team
Claire Roberson PhD, CEO/President
Chantal Miklosi, CFO
Nasir Khan , Co-Founder
Rasheed Tijani, Co-Founder